Geron Corporation (BIT:1GERN)

Italy flag Italy · Delayed Price · Currency is EUR
1.133
-0.017 (-1.52%)
At close: Sep 25, 2025
-9.62%
Market Cap 703.87M
Revenue (ttm) 140.03M
Net Income (ttm) -74.94M
Shares Out n/a
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 450
Average Volume 223
Open 1.189
Previous Close 1.150
Day's Range 1.133 - 1.189
52-Week Range 1.000 - 1.390
Beta n/a
RSI 38.57
Earnings Date Nov 6, 2025

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 229
Stock Exchange Borsa Italiana
Ticker Symbol 1GERN
Full Company Profile

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.